Presentation is loading. Please wait.

Presentation is loading. Please wait.

Epstein-Barr virus re-activation in post-kidney transplant period: risk factors and specific immune- responses Erica Franceschini.

Published byPatricia Annice Nichols Modified over 7 years ago

Similar presentations

Presentation on theme: "Epstein-Barr virus re-activation in post-kidney transplant period: risk factors and specific immune- responses Erica Franceschini."— Presentation transcript:

1 Epstein-Barr virus re-activation in post-kidney transplant period: risk factors and specific immune- responses Erica Franceschini

2 KDIGO guidelines suggest monitoring high-risk (donor EBV seropositive/recipient seronegative) kidney renal transplants for EBV by NAT Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre- emptive reduction of immunosuppression EBV monitoring 85.9% 77.4% pre-emptive treatment for patients with significant EBV DNAemia levels Background B. Kasiske et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary R. San-Juan et al. Clin Microbiol Infect 2015

3 Objectives Evaluation of the incidence of EBV re-activation in the post-kidney transplant period in the Modena cohort Evaluation of EBV re-activation risk factors Evaluation of the probability to develop a PTLD once a patient has an EBV re-activation

4 Patients and Methods Retrospective observational study All consecutive patients who performed a quantitative EBV-DNA assay in the post-KT period from January 2005 to December 2014 Patients with negative EBV-DNA were compared to patients with positive EBV-DNA Patients with EBV-VL >4,000 copies/ml were compared to patients with EBV-VL <4,000 copies/ml D.Rowe et al. Epstein–Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease

5 Results 523 kidney transplants, 4175.3 person year follow-up (PYFU) 265 kidney transplants (50.7%) performed in Modena 340 (65.0%) males Median age 46 years (IQ 35-57) 44 (8.4%) living-donor transplant 190 (36.3%) screened for EBV-DNA, 1768.8 PYFU 128 (67.4%) out of 190 EBV-DNA positive

6 Characteristics of EBV-positive and EBV-negative patients EBV-positive N= 128 EBV-negative N= 62 p-value Sex Women, n (%) Men, n (%) 45 (35.16) 83 (64.84) 16 (25.81) 46 (74.19) 0.246 Age, mean (SD) (years)46 (±14.21)50 (±13.41)0.104 Acute rejection, n (%)20 (15.62)11 (17.74)0.834 KT primary indication, n (%) Glomerulonephritis Chronic pyelonephritis Obstructive nephropathy Haemolytic uraemic syndrome Trauma Unknown 53 (41.41) 40 (31.25) 13 (10.16) 6 (4.69) 0 (0) 16 (12.50) 26 (41.94) 21 (33.87) 7 (11.29) 3 (4.84) 0 (0) 5 (8.06) 0.928

7 EBV-positive N= 128 EBV-negative N= 62 p-value Epstein-Barr recipient serostatus, n (%) Positive Negative Missing 52 (40.62) 3 (2.34) 73 (57.03) 33 (53.22) 2 (3.22) 27 (43.54) 0.195 Re-KT, n (%)6 (4.69)2 (0.50)0.003 HCV-positive, n (%)9 (7.03)5 (8.06)0.774 HIV-positive, n (%)5 (3.91)3 (4.84)0.717 Comorbidities, n (%)93 (72.66)39 (62.90)0.182 Graft failure, n (%)15 (11.72)9 (14.52)0.643 Time between KT and graft failure, median (IQR) (days) 1,834 (415-4,389) 522 (91-3,098) 0.029 Patient death, n (%)8 (6.25)10 (16.12)0.036 CMV re-activation, n (%) Missing Negative Positive 38 (31.93) 73 (61.34) 8 (6.72) 15 (28.84) 34 (65.38) 3 (5.77) 0.926

8 EBV-positive N= 128 EBV-negative N= 62 p-value Polyoma virus BK re-activation, n (%) Missing Negative Positive 66 (55.46) 37 (31.09) 16 (13.44) 27 (51.92) 16 (30.77) 9 (17.31) 0.825 Number of samples tested for EBV-VL, median (IQR) 2 (1-5)1 (1-1)<0.001 Induction therapy, n (%) Basiliximab Thymoglobulin Daclizumab Not done 60 (46.87) 9 (7.03) 1 (0.78) 58 (45.31) 33 (53.22) 4 (6.45) 1 (1.61) 24 (38.70) 0.713 Creatinine value at EBV-VL sample, median (IQR) (mg/dl) 1.67 (1.33-2.43) 1.61 (2.25-2.20) 0.437 PTLD, n (%)6 (4.68)3 (4.83)1.000

9 Univariate Poisson regression analysis for factors associated with EBV re-activation VariableIRR95% CIp Age, per 1 year1.031.02-1.04<0.001 Men vs Women1.130.81-1.580.471 Creatinine0.970.88-1.060.520 Induction: Thymoglobulin vs Basiliximab None vs Basiliximab 0.73 0.09 0.37-1.41 0.06-0.12 0.349 <0.001 Cyclosporine1.350.97-1.890.075 Micofenolic acid1.310.89-1.930.166 Sirolimus1.991.18-3.350.009 Everolimus2.421.62-3.60<0.001 Tacrolimus1.470.97-2.220.068 Steroid1.861.27-2.73<0.001 Azathioprine0.850.42-1.750.674

10 Characteristics of patients with EBV-VL > 4,000 copies/ml 19 patients out of 128 (14.8%) EBV viral load superior to 4,000 copies/ml (IR 1.07/100 PYFU, 95% CI 0.65-1.68) No statistically significant differences between patients with EBV-VL> 4,000 copies/ml and EBV-VL < 4,000 copies/ml The use of MPA and steroids resulted as risk factors for EBV re-activation with EBV-VL superior to 4,000 copies/ml in the univariable analysis

11 Post Transplant Lymphoproliferative Diseases 9 patients out of 523 (1.7%) had a PTLD IR of PTLD in KT population was 0.19/100 PYFU (0.09 – 0.37) IR of PTLD in patients tested for EBV-VL was 0.50/100 PYFU (0.23-0.95) 1 EBV-related PTLD 8 non EBV-related PTLD

12 Characteristics of population with PTLD AgeSexEBV IgG Induction Therapy Manteinance Therapy Time KT- PTLD EBV-VL (copies/ ml) PTLD type SymptomsPTLD type Histological examination Patient 1 21MR-BASSteroids CSA 9 months 79B- DL L ymphonode enlargement earlypositive Patient 2 68MR+BASCSA Steroids EVR 8 years61B-NHL L ymphonode enlargement cytopenia latenegative Patient 3 31FNABAS Steroid TAC SIR 12 years 342B-DLSweats Fever L ymphonode enlargement latenegative

13 Patient 7 22MNAnoCSA13 yearsnegLGLcytopenialatenegative Patient 8 59FR+BSAEVR4 yearsnegLGLnolatenot done Patient 9 41MNAnoCSA Steroid 15 yearsnegMMSplenomegalylatenegative Patient 4 55MR+ATGTAC Steroid 3 years80LGLnolatenot done Patient 5 63FNAnoCSA Steroid MPA 11 years 697MMnolatenegative Patient 6 46MR+BSACSA8 years53NML L ymphonode enlargement latenegative AgeSexEBV IgG Induction Therapy Manteinance Therapy Time KT- PTLD EBV-VL (copies/ ml) PTLD type SymptomsPTLD type Histological examination

14 Univariate Poisson regression analysis for factors associated with PTLD VariableIRR95% CIp Age, per 1 year1.010.96-1.060.571 Men vs Women0.920.23-3.690.911 Creatinine1.080.75-1.560.679 Induction: ATG vs BAS None vs BAS 1.54 0.51 0.17-13.81 0.12-2.50 0.698 0.347 CSA1.050.23-4.690.947 SIR2.170.26-18.050.472 EVR1.390.16-11.580.758 TAC3.030.58-15.600.185 Steroid0.640.15-2.890.570

15 Conclusions Importance of initial EBV serologic screening of the candidate Despite the literature suggests the importance of quantitative EBV viral load monitoring for PTLD prevention in high-risk populations in the first year the only case of early PTLD in our study had a low VL Avoid EBV viral load assays performing in low risk patients or after the first year post-transplant in absence of a strong PTLD suspicion Importance of PTLD clinical suspicion

16 Thanks to… Mauro Codeluppi Patrizia Comoli Delia Davoli Margherita Digaetano Jessica Plessi Leonardo Potenza Elisabetta Rubbiani Antonella Santoro Stefano Zona Cristina Mussini

Download ppt "Epstein-Barr virus re-activation in post-kidney transplant period: risk factors and specific immune- responses Erica Franceschini."

Similar presentations

ID Week, Philadelphia October 7-12 2014 Clinically Applied Variation in Replication Kinetics During Episodes of Post-Transplant Cytomegalovirus (CMV) Infections.

ID Week, Philadelphia October Clinically Applied Variation in Replication Kinetics During Episodes of Post-Transplant Cytomegalovirus (CMV) Infections.
Everolimus plus Reduced-Exposure CsA is as Effi cacious as Mycophenolic Acid plus Standard-Exposure CsA Reference: Silva Jr HT, Cibrik D, Johnston T, et.

Everolimus plus Reduced-Exposure CsA is as Effi cacious as Mycophenolic Acid plus Standard-Exposure CsA Reference: Silva Jr HT, Cibrik D, Johnston T, et.
POSTER TEMPLATE BY: www.PosterPresentations.com Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) Features of.

POSTER TEMPLATE BY: Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) Features of.
© 2014 Direct One Communications, Inc. All rights reserved. 1 Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin–Madison.

© 2014 Direct One Communications, Inc. All rights reserved. 1 Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin–Madison.
6-Month Universal CMV Prophylaxis - Safety and Efficacy in Kidney Transplant Patients Induced with Alemtuzumab: A Single Center Retrospective Study Lakshmi.

6-Month Universal CMV Prophylaxis - Safety and Efficacy in Kidney Transplant Patients Induced with Alemtuzumab: A Single Center Retrospective Study Lakshmi.
Superior outcomes in HIV-positive kidney transplant patients compared to HCV-infected or HIV/HCV co-infected recipients Deirdre Sawinski MD, Kimberly A.

Superior outcomes in HIV-positive kidney transplant patients compared to HCV-infected or HIV/HCV co-infected recipients Deirdre Sawinski MD, Kimberly A.
Charcot neuroarthropathy after Simultaneous Pancreas Kidney transplantation: risk factors and evolution of prevalence over 20 years. Prof. Dr. GA Matricali.

Charcot neuroarthropathy after Simultaneous Pancreas Kidney transplantation: risk factors and evolution of prevalence over 20 years. Prof. Dr. GA Matricali.
POLYOMAVIRUS INFECTION IN RENAL ALLOGRAFTS: PROGRESS SINCE BANFF 1999 Parmjeet Randhawa Associate Professor Division of Transplantation Pathology Department.

POLYOMAVIRUS INFECTION IN RENAL ALLOGRAFTS: PROGRESS SINCE BANFF 1999 Parmjeet Randhawa Associate Professor Division of Transplantation Pathology Department.
Recent management of Renal Transplantation in a Developing Country like Bangladesh, R Alam, Islam M S, R Alam, H Rahman, HU Rashid Department of Nephrology,

Recent management of Renal Transplantation in a Developing Country like Bangladesh, R Alam, Islam M S, R Alam, H Rahman, HU Rashid Department of Nephrology,
USRDS Clinical Indicators of Renal Allograft Loss Lawrence Y.C. Agodoa, MD FACP Jon J. Snyder, MS Bertram L. Kasiske, MD Allan J. Collins, MD FACP United.

USRDS Clinical Indicators of Renal Allograft Loss Lawrence Y.C. Agodoa, MD FACP Jon J. Snyder, MS Bertram L. Kasiske, MD Allan J. Collins, MD FACP United.
Sum Scores and Scores of Individual Components in Clinical Practice and Clinical Trials Lillian W. Gaber University of Tennessee.

Sum Scores and Scores of Individual Components in Clinical Practice and Clinical Trials Lillian W. Gaber University of Tennessee.
EBV Protocol 8.26.14. Data From UNOS Summary Stats 1988-2014 CASU + 2009-2014 CAPC OrganTotalPTLDPercent PTLDPercent PTLD in Literature Heart2942173-9.

EBV Protocol Data From UNOS Summary Stats CASU CAPC OrganTotalPTLDPercent PTLDPercent PTLD in Literature Heart
CM-1 Clinical Transplantation Lung Howard University Hospital Department of Transplantation Clive O. Callender, MD. Arturo Hernandez, MD.

CM-1 Clinical Transplantation Lung Howard University Hospital Department of Transplantation Clive O. Callender, MD. Arturo Hernandez, MD.
Post Transplant Lymphoproliferative Disorders (PTLD)

Post Transplant Lymphoproliferative Disorders (PTLD)
Optimizing CMV Prevention Sharon F. Chen, MD, MS Hayley Gans, MD February 19, 2015.

Optimizing CMV Prevention Sharon F. Chen, MD, MS Hayley Gans, MD February 19, 2015.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.

Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Monitoring HLA-specific antibodies

Monitoring HLA-specific antibodies
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095.

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.

Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient.

1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient.

Similar presentations

Ads by Google